AB

Ab Science (AB)

Ab Science

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:EU:AB

1 2 3 4 5 6 7 8 9 10 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
31/05/2024	16h30	GlobeNewswire Inc.	AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS	EU:AB	Ab Science
31/05/2024	16h30	GlobeNewswire Inc.	AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS	EU:AB	Ab Science
31/05/2024	16h30	GlobeNewswire Inc.	AB Science fournit un résumé de la conférence virtuelle qui s'est tenue le 30 mai 2024, faisant le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA	EU:AB	Ab Science
29/05/2024	18h02	GlobeNewswire Inc.	AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA	EU:AB	Ab Science
29/05/2024	18h02	GlobeNewswire Inc.	AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS	EU:AB	Ab Science
29/05/2024	18h02	GlobeNewswire Inc.	AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS	EU:AB	Ab Science
17/05/2024	17h58	GlobeNewswire Inc.	AB Science communique un rectificatif sur les comptes consolidés au 31 décembre 2023	EU:AB	Ab Science
15/05/2024	20h16	GlobeNewswire Inc.	AB Science reports its revenues for the year 2023 and provides an update on its activities	EU:AB	Ab Science
15/05/2024	20h16	GlobeNewswire Inc.	AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2023 et présente un point sur ses activités	EU:AB	Ab Science
15/05/2024	20h16	GlobeNewswire Inc.	AB Science reports its revenues for the year 2023 and provides an update on its activities	EU:AB	Ab Science
13/05/2024	18h08	GlobeNewswire Inc.	AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036	EU:AB	Ab Science
13/05/2024	18h08	GlobeNewswire Inc.	AB Science annonce la délivrance d’un brevet européen pour le masitinib dans le traitement de la mastocytose sévère avec une protection jusqu’en 2036	EU:AB	Ab Science
13/05/2024	18h08	GlobeNewswire Inc.	AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036	EU:AB	Ab Science
07/05/2024	18h05	GlobeNewswire Inc.	AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient	EU:AB	Ab Science
07/05/2024	18h05	GlobeNewswire Inc.	AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient	EU:AB	Ab Science
07/05/2024	18h05	GlobeNewswire Inc.	AB Science:	EU:AB	Ab Science
02/05/2024	19h14	GlobeNewswire Inc.	AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science	EU:AB	Ab Science
02/05/2024	19h14	GlobeNewswire Inc.	AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science	EU:AB	Ab Science
02/05/2024	19h14	GlobeNewswire Inc.	AB Science : La Cour d’Appel de Paris confirme la mise hors de cause du Président Directeur Général d’AB Science, Alain Moussy, et diminue le montant de la sanction imposée à AB Science	EU:AB	Ab Science
30/04/2024	18h56	GlobeNewswire Inc.	AB Science announces a slight delay in the publication of its 2023 annual financial report	EU:AB	Ab Science
30/04/2024	18h56	GlobeNewswire Inc.	AB Science announces a slight delay in the publication of its 2023 annual financial report	EU:AB	Ab Science
30/04/2024	18h56	GlobeNewswire Inc.	AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023	EU:AB	Ab Science
03/04/2024	18h08	GlobeNewswire Inc.	AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA	EU:AB	Ab Science
03/04/2024	18h08	GlobeNewswire Inc.	AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS	EU:AB	Ab Science
13/03/2024	12h58	GlobeNewswire Inc.	AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease	EU:AB	Ab Science
13/03/2024	12h58	GlobeNewswire Inc.	AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune	EU:AB	Ab Science
13/03/2024	12h58	GlobeNewswire Inc.	AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease	EU:AB	Ab Science
07/03/2024	15h20	GlobeNewswire Inc.	AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development	EU:AB	Ab Science
07/03/2024	15h20	GlobeNewswire Inc.	AB Science propose un résumé de la conférence virtuelle qui s’est tenue le 4 mars 2024, avec pour objectif de faire le point sur le développement d'AB Science	EU:AB	Ab Science
07/03/2024	15h20	GlobeNewswire Inc.	AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development	EU:AB	Ab Science